2. Nanda R, Liu MC,Yau C, et al. Effect of Pembrolizumab Plus NeoadjuvantChemotherapy on Pathologic Complete Response in Women With Early-Stage BreastCancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 TrialJAMA Onco...
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early- stage HER2- positive breast cancer (Neo Sphere): a multicentre, open- label, phase 2 randomised trial[J].Lancet On...
2. Nanda R, Liu MC,Yau C, et al. Effect of Pembrolizumab Plus NeoadjuvantChemotherapy on Pathologic Complete Response in Women With Early-Stage BreastCancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 TrialJAMA Oncol.2020 May 1;6(5):676-684. 3.I-SPY2 Trial Consortiu...
[11]Mougalian SS,Soulos PR,Killelea BK,et al.Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States.Cancer.2015;121:2544–2552. [12]Chen S,Liang Y,Feng Z,et al.Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab ...
近日，来自美国耶鲁大学的Lajos Pusztai团队在Cancer Cell上在线发表题为Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial 的文章，报道了一项用于II/III期早期乳腺癌的I-SPY2试验结果，显示度伐利尤与奥拉帕尼...
[17]Ismael G, Hegg R, et al.Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol. 2012 Sep;13(9):869-78. ...
[2] Tarantino P, Jin Q, Tayob N, et al. Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer. JAMA Oncol. 2022;8(8):1177–1183. [3] Barros-Silva JD, Leitão D, Afonso L, et al. Association of ERBB2 gene status with histopathological parameters...
参考文献: Marra, Antonio et al. “Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives.” Nature reviews. Clinical oncology vol. 21,3 (2024): 185-202. doi:10.1038/s41571-023-00849-9...
1、Peter Schmid, et al.Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage Triple-Negative Breast Cancer: Updated Event-Free Survival Results From the Phase 3 KEYNOTE-522 Study. 2023 SABCS abstract #LBO1-01. ...
[4]Neoadjuvant ipilimumab and nivolumab in combination with paclitaxel following anthracycline-based chemotherapy in patients with treatment resistant early-stage triple-negative breast cancer (TNBC): A single-arm phase 2 trial. | Journal of Clinical Oncology ...